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Background: Hepatitis B virus (HBV) infection is a major health concern with more than two billion individuals
currently infected worldwide. Because of the limited effectiveness of existing vaccines and drugs, development of
novel antiviral strategies is urgently needed. Heat stress cognate 70 (Hsc70) is an ATP-binding protein of the heat
stress protein 70 family. Hsc70 has been found to be required for HBV DNA replication. Here we report, for the first
time, that combined siRNAs targeting viral gene and siHsc70 are highly effective in suppressing ongoing HBV
expression and replication.
Methods: We constructed two plasmids (S1 and S2) expressing short hairpin RNAs (shRNAs) targeting surface open
reading frame of HBV(HBVS) and one plasmid expressing shRNA targeting Hsc70 (siHsc70), and we used the
EGFP-specific siRNA plasmid (siEGFP) as we had previously described. First, we evaluated the gene-silencing efficacy
of both shRNAs using an enhanced green fluorescent protein (EGFP) reporter system and flow cytometry in HEK293
and T98G cells. Then, the antiviral potencies of HBV-specific siRNA (siHBV) in combination with siHsc70 in
HepG2.2.15 cells were investigated. Moreover, type I IFN and TNF-α induction were measured by quantitative
real-time PCR and ELISA.
Results: Cotransfection of either S1 or S2 with an EGFP plasmid produced an 80%–90% reduction in EGFP signal
relative to the control. This combinational RNAi effectively and specifically inhibited HBV protein, mRNA and HBV
DNA, resulting in up to a 3.36 log10 reduction in HBV load in the HepG2.2.15 cell culture supernatants. The
combined siRNAs were more potent than siHBV or siHsc70 used separately, and this approach can enhance
potency in suppressing ongoing viral gene expression and replication in HepG2.2.15 cells while forestalling escape
by mutant HBV. The antiviral synergy of siHBV used in combination with siHsc70 produced no cytotoxicity and
induced no production of IFN-α, IFN-β and TNF-α in transfected cells.
Conclusions: Our combinational RNAi was sequence-specific, effective against wild-type and mutant drug-resistant
HBV strains, without triggering interferon response or producing any side effects. These findings indicate that
combinational RNAi has tremendous promise for developing innovative therapy against viral infection.
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More than 350 million of about 2 billion people in the
world exposed to the hepatitis B virus (HBV) are chron-
ically infected and at serious risk of developing liver fail-
ure, cirrhosis, and hepatocellular carcinoma (HCC)
[1–3]. About 75% of them reside in the Asia-Pacific re-
gion [4], particularly in Asian endemic areas such as
China. Each year, ~600,000 HBV-related deaths occur
worldwide [5]. Approved therapies for chronic hepatitis
B include interferon (IFN)-alfa and nucleos(t)ide analo-
gues, but rarely eliminate the virus [6]. HBV persists by
establishing HBV covalently closed circular DNA (ccc
DNA) in hepatocytes, which nuclear transcription tem-
plate continues to initiate new HBV replication cycle
even after serologic clearance. Long-term treatment in
most cases bears the risk of adverse side-effects and mu-
tant drug-resistant HBV strains. Therefore, combin-
ational strategies for treating HBV from different angles
are urgently needed. In infected hepatocytes, HBV pro-
duces four major classes of messenger RNAs (mRNAs).
A 3.5 kb pregenomic RNA is reverse-transcribed into
new HBV genomes and serves as mRNA for translating
the viral core and polymerase proteins. A minimally
longer RNA encodes the secretory hepatitis B e antigen
(HBeAg). RNAs (2.4 and 2.1 kb) serve as mRNA for viral
envelope proteins L, M, and S. From 0.7 kb RNA the
HBV X protein is translated (Additional file 1: Figure S1).
RNA interference (RNAi) is a sequence-specific post-
transcriptional gene-silencing molecular mechanism that
was first discovered in Caenorhabditis elegans [7]. RNAi
process is initiated by an RNase III enzyme known as
Dicer that processes dsRNAs into 21–25 nt small inter-
fering RNAs (siRNAs). Subsequently, these siRNAs are
unwound, and one strand is preferentially loaded into
the RNA-induced silencing complex (RISC). The loaded
single-stranded RNA, called the antisense guide strand,
then directly targets the complementary mRNA for
cleavage or transcriptional repression and degradation,
with the other strand — the ‘passenger’ — being de-
graded [8–11]. RNAi can be induced via synthetic siR-
NAs [12] or DNA vectors for intracellular expression of
short hairpin RNAs (shRNAs) [11,13]. RNAi-based gene
silencing approaches have been demonstrated in
humans, and ongoing clinical trials hold promise for
treating fatal disorders or providing alternatives to trad-
itional small molecule therapies [11]. There have been
many studies reporting on highly effective RNAi-
mediated silencing of human immunodeficiency virus
type 1(HIV-1) [14–16], HBV [17–21], hepatitis C virus
(HCV) [22,23], hepatitis E virus [24], influenza virus
[25], SARS-CoV [26] and Ebola filoviruses [27] in cell
culture and in vivo. In addition, some siRNAs have been
found to be potent sequence-dependent inductions of
the mammalian innate immune response [28–31]; theyare also reported to be possessed of bifunctional antiviral
molecules that induce production of type I IFNs in the
liver and target HBV to inhibit viral replication [21].
However, technical challenges remain, such as how to
deliver siRNAs specifically into target genes in a thera-
peutically acceptable way [11,32,33] while avoiding ad-
verse side effects [34].
HBV strains rely heavily on host cell machinery to
complete their life cycles. A number of host proteins
have been found to be crucial for HBV/ HCV replication
[35–39]. Hsc70 (or HspA8) is an ATP-binding protein of
the Hsp70 family [40]. This host protein has been found
to be required for the reverse transcription process in
HBV DNA replication [41, 42]. Host proteins can also
be targeted, for example siRNAs directed to both diacyl-
glycerol acyltransferase 1 (DGAT1) and the host gene
product polo-like kinase 1 (PLK1) can reduce HCV pro-
duction [43,44]. Notably, Nakagawa et al. and Liu et al.
[38,45,46] have demonstrated that down-regulation of
Hsp70 or Hsp90 by siRNA significantly inhibited HBV/
HCV production with no cytotoxicity, cellular prolifera-
tion or apoptosis. A current focus of several laboratories
is to use miRNA or shRNA expression methods to target
more than one viral transcript [47–49]. As chronic hepa-
titis contributes significantly to hepatocellular carcinoma
pathogenesis, this further stimulates interest in new
HBV therapies to reduce disease burden.
We [33,50–57] previously showed sequence-specific
inhibition by RNAi of HBV/HCV/FMDV and EGFP
in vitro and in vivo. Recently we [58] reported that
Japanese encephalitis virus infection in Huh7 cells pre-
supposes the association of Hsp70 with lipid rafts, and
HBV has been demonstrated to promote tumor cell in-
vasion by a mechanism involving the up-regulation of
heat shock protein 90 (Hsp90) [59]. There has so far been
no report on using the siHBV and endogenous Hsc70 tar-
geting (siHsc70) combination to treat HBV. Here we dem-
onstrate that siHBV in combination with siHsc70 in
HepG2.2.15 cells is an innovative effective approach to
treating HBV without triggering innate immune response,
and that their antiviral synergy produces no cytotoxicity
and does not affect cell viability or proliferation.
Results
siRNAs effectively suppressed the expression of fusion
EGFP in HEK293 and T98G cells
The siRNAs targeted to the conserved regions of HBV
genome were generated by intracellular Dicer enzyme,
as depicted in Additional file 1: Figure S1A. To identify
an effective inhibitory efficacy of siRNAs, the DNA cas-
settes of these regions were inserted into the 5’ end of
enhanced green fluorescent protein (EGFP) gene to con-
struct reporter plasmids (Additional file 1: Figure S1B).
The reporter plasmids were transfected into HEK293






































Figure 1 (See legend on next page.)
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Figure 1 Effect of siRNAs on the expression of HBV surface open reading frame in HEK293 and T98G cells. (A) As shown in Additional
file 2: Figure S2. (B) Fluorescence micrographs of cells transfected with reporter plasmids and cotransfected with either the corresponding or
non-corresponding siRNA with Lipofectamine TM 2000 (Invitrogen). At 24 hrs after transfection, the cells were observed with an Olympus BH-2
microscope, and representative bright-field images (left column) and relative fluorescent-field images (right column) were recorded by tenfold
amplification. (C) Flow cytometry analysis of siRNA-mediated gene silencing of EGFP. Level of EGFP expression in cells cotransfected with (a)
pEGFP-N1 vector; ( b) pS-EGFP-N1 and pU6; (c) pS-EGFP-N1 and S1; (d) pS-EGFP-N1 and S2; (e) pS-EGFP-N1 and S3 (heterologous siRNA). (D) Cells
were analyzed for EGFP expression by fluorescence-activated cell sorting and the level of fluorescence relative to the control was quantitated.
The mean fluorescence intensity of control siRNA was taken as 100% and adopted as control. Data represent means±SD from three independent
experiments were performed in triplicate.*Significant differences compared to the heterologous siRNA control: Student’s t-test; P < 0.05.
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the heterologous siRNAs.The number of EGFP-
expressing cell was examined by fluorescent microscope
24 h after transfection so as to the verification of an
RNAi-mediated mechanism. We found that the number
of cells in visible light were comparable in cells trans-
fected with homologous siRNAs relative to cells trans-
fected with heterologous siRNAs or non-transfected
cells. This indicates that siEGFP does not vitiate cellular
growth and survival. After green fluorescent light was
put into action, it could be seen that in comparison with
the other groups, the expressivity of EGFP decreased
markedly in the siEGFP group. This indicates that in
addition to impacting post-transcriptional translation,
siEGFP exercised its specific, gene-silencing effect on
the EGFP, resulting in cessation of EGFP expression
(Figure 1A, B and Additional file 2: Figure S2A). The ex-
pression of EGFP was determined by flow cytometry,
and the same conclusion was reached by making a
comparison of the different groups (Figure 1C, D and
Additional file 2 Figure S2B). Statistically significant
differences existed between the siEGFP group and the
controls (P < 0.05). This was further confirmed with
Western blotting by assessing siEGFP inhibition of the
expression of EGFP fusion protein and produced the
same results (data not shown). These results demon-
strate that shRNAs have been generated from siRNA-
expressing plasmid and efficiently processed by intracel-
lular Dicer enzyme turn into corresponding siRNAs as
RNAi on the target gene (Figure 1). Cotransfection of either
S1 or S2 with a reporter plasmid produced an 80%–90%
reduction in EGFP signal relative to the control.
Fluorescence-activated cell sorting demonstrated that
the levels of inhibition mediated by the siRNAs were
similar among the different experiment groups and sig-
nificantly higher than the control group (cotransfection
with heterologous siRNAs or without siRNAs). To fur-
ther detect inhibitory effectiveness, cells were collected
48 h after transfection and the inhibitory potency of
siRNAs was assessed by quantitative real-time PCR and
reverse transcription-PCR (RT-PCR) assay. The level of
target RNAs was significantly reduced in cells trans-
fected with homologous siRNAs, and the specific amp-
lification of RT-PCR products confirmed by Melt-curveanalysis (data not shown). The inhibition of EGFP and S
mRNA expression were also demonstrated by RT-PCR
analysis [33,50,56]. The correct transcription of EGFP and
S was confirmed by sequencing of RT-PCR products. The
results suggested that the siRNAs generated by intracellu-
lar transcription could effectively and specifically inhibit
the expression of HBV in transfected cells.
Synergistic inhibition of HBV protein expression by siHBV
in combination with siHsc70 in HepG2.2.15 cells
To determine the knockdown efficacy of shRNA expres-
sion cassettes that target the HBVS when used alone or
in combination with a hairpin expression cassette that
targeted the endogenous Hsc70, the amount of HBsAg
and HBeAg in the cell culture supernatant was deter-
mined using ELISA at different time points after trans-
fection. As depicted in Figure 2B and C, the S1 and S2
can independently and significantly inhibit HBsAg and
HBeAg 48 h after transfection. The HBsAg was reduced
60.7% by S1 and 72.7% by S2, while the HBeAg
decreased 56.9% with S1 and 69.8% with S2, as com-
pared with the heterologous siRNA control (P < 0.05).
As shown in Figure 2A, the expression of Hsc70 was
abrogated by siHsc70, as compared with control. The
reductions of HBsAg and HBeAg were about 60.2% and
61.2% individually by siHsc70 at 48 h after transfection,
while the combination of S2 and siHsc70 markedly
inhibited 89.1% of HBsAg and 89.6% of HBeAg individu-
ally in the supernatants of HepG2.2.15 cells 72 h after
tansfection with S2 and siHsc70, as compared with the
homologous siRNA or the heterologous siRNA (P < 0.05).
The results indicated that the combined siRNAs were
more potent than the siHBV or siHsc70 used separately.
Specific inhibition of HBVS mRNA by siHBV in
combination with siHsc70 in HepG2.2.15 cells
As depicted in Figure 3A, the S1, S2, and siHsc70 could
effectively and specifically inhibit the expression of
HBVS gene 24 h after transfection, with reduction of
HBVS mRNA by 63.4%, 72.2% and 69.2% respectively
48 h after transfection, whereas the heterologous siRNA
control revealed no significant effects on HBVS mRNA
in HepG2.2.15 cells. When the S2 was used in combin-
ation with siHsc70, their synergistic inhibition of HBVS
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that the combined siRNAs were more potent than S2 or
siHsc70 used individually. The results showed that com-
binational RNAi effectively and specifically inhibited the
expression of HBVS mRNA.
Specific inhibition of HBV DNA by siHBV in combination
with siHsc70 in HepG2.2.15 cells
As depicted in Figure 3B, as compared with the controls,
HBV DNA decreased distinctly in cell culture superna-
tants 24 h after transfection with plasmids S1, S2,
siHsc70 or S2 and siHsc70 respectively, with their in-
hibitory effects most noticeable 72 h after transfection.
The HBV DNA copies in S1, S2 or siHsc70 treated cells
was found to have been reduced by 2.44 log10, 2.64 log10
and 3.04 log10 respectively 72 h after transfection, while
the combination of siHsc70 and S2 produced a 3.36
log10 decrease in HBV load of the cell culture superna-
tants. The controls did not showed a significant reduc-
tion from the heterologous siRNA at any time point.
Thus siRNAs of the HBV genome targeting and en-
dogenous gene targeting combination were effective and
specific, and resulted in an overall reduction of virus
load, which indicated that the combined siRNAs were
more potent than the siHBV or siHsc70 used separately.
Silencing Hsc70 does not affect cell viability
Hsc70 are highly-conserved essential stress proteins.
Therefore, we next investigated whether gene-silencing
of host protein affected cell viability and consequently
viral production. An MTT assay, measured at A570,
determined that siRNA-mediated silencing of Hsc70 had
no significant effect on cellular proliferation (or cytotox-
icity). A GAPDH Western blotting was used as an in-
ternal control to verify that equivalent numbers of cells
were used in each assay. These results indicate that
siRNA-mediated gene silence of Hsc70 does not affect
cell viability.
Effects of siRNAs on IFN-α, IFN-β, TNF-α in HEK293, T98G
cells and HepG2.2.15 cells
We investigated whether the IFN pathway induction
could be stimulated in siRNA transfected cells as
reported in earlier studies [28–31]. The results showed
that positive-control poly (I:C) caused intense IFN-β
secretion in HEK293 and HepG2.2.15 cells, while the
siRNAs induced no production of IFN-α, IFN-β and
TNF-α in transfected cells (Figure 4A and B), and
IFN-α, IFN-β and TNF-α mRNA concentrations were
not detected in T98G cells as measured by ELISA and
RT- PCR (Figure 4C and D). By combining with receptor
TLR3, the IFN-β response generated by the poly (I:C) as
IFN activated the downstream signal pathway to induce
releases of type I IFN. As can be seen in Figure 4, thepoly (I:C) induced strong IFN response in HEK293 cells,
resulting in massive IFN-β expression and no IFN-α or
TNF-α expression. A comparison with these cells not
transfected with any plasmid revealed that the impact of
S1, S2, S3, siHsc70, and siEGFP on production of type I
IFN and TNF-α in transfected cells was negligible or no
immunostimulation. Taken together, we showed that the
poly (I:C) could not induce IFN response in T98G cells,
which indicates that expression by receptor TLR3 in
T98G cells were little to none. We found that the
siRNAs tested did not induce the innate IFN response
whereas the poly (I:C) control was a good stimulator.
Discussion
In this study, we showed for the first time that combined
siRNAs targeting the genes of HBVS and siHsc70 is spe-
cific and highly effective in suppressing ongoing viral
gene expression and replication in HepG2.2.15 cells
while forestalling escape by mutant HBV. The combined
siRNAs were more potent than siHBV or siHsc70 used
separately, without triggering IFN response or producing
any side effects. In agreement with research by Liu et al.
[45], our work demonstrates that the antiviral synergy of
siHBV used in combination with siHsc70 produces no
cytotoxicity and does not affect cell viability. Recently,
modular trimeric Pol II expression cassettes comprising
miRNA shuttles have been used successfully to generate
multiplexed anti-HBV RNAi activators [60]. We con-
structed plasmids siHBV and siHsc70, and employed an
HBV genes targeting and endogenous Hsc70 genes tar-
geting combination, while Ely et al. [60] reported that
they constructed miR expression plasmids, and gener-
ated cassettes using primiR-31-, pri-miR-30a- and pri-
miR-122-derived modules, which were combined as
trimers and expressed from a Pol II promoter. The plas-
mids we constructed and the combinational approach
we adopted are markedly different from those Ely et al.
did. Interestingly, their study and ours produced the
same results [60].
Molecular chaperones were initially discovered as
mediators of the cellular heat shock response [61], and
subsequent studies have demonstrated promiscuous
functions for these proteins, including those related to
both cancer- and virus-associated pathogenesis [62]. The
heat stress protein 70 (Hsp70) family is composed of
highly conserved proteins, including Hsc70, Hsp70, heat
shock protein 90 (Hsp90) , GRP75 and GRP88. Hsc70
(or Hsp90) is a well-characterized, multifunctional mo-
lecular chaperone involved in regulation of signal trans-
duction, transcriptional activation, oncogenic protein
stabilization, and neovascularization—pathogenic ele-
ments relevant to viral cancer pathogenesis [62]. Despite
functioning primarily as cytoplasmic chaperones, these
family members are found on the surfaces of various cell
BC
A
Figure 2 Synergistic inhibition of HBV protein expression by siRNA targeting viral gene in combination with siHsc70 in HepG2.2.15
cells. (A) The expression of Hsc70 in HepG2.2.15 cells transfected with siHsc70 or siCtrl after 72 hrs was identified by Western blotting with anti-
Hsc70. GAPDH expression was used as an internal control. (B) The reduction of HBsAg expression. HepG2.2.15 cells transfected with pU6, S1, S2,
siHsc70, S2 with siHsc70, and also the heterologous S3. (C) The reduction of HBeAg expression. HepG2.2.15 cells transfected with pU6, S1, S2,
siHsc70, S2 with siHsc70, and also the heterologous S3. Data represent means±SD from three independent experiments were performed in
triplicate.*Significant differences compared to the heterologous siRNA control: Student’s t-test; P < 0.05.
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Figure 3 Specific inhibition of HBV genes by siRNA targeting viral gene in combination with siHsc70 in HepG2.2.15 cells. (A) The
inhibition of HBVS mRNA by siRNAs at different time points. HepG2.2.15 cells were transfected with pU6, S1, S2, siHsc70, S2 with siHsc70, and also
the heterologous S3. Data represent means±SD from three independent experiments were performed in triplicate. *Significant differences
compared to the heterologous siRNA control: Student’s t-test; P < 0.05. (B) Inhibition of HBV DNA by siRNAs in cell culture supernatants.
HepG2.2.15 cells were transfected with pU6, S1, S2, siHsc70, S2 with siHsc70, and also the heterologous S3. Data represent means±SD from three
independent experiments were performed in triplicate.
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genic cells, epidermal cells, arterial smooth muscle cells,
monocytes and B-cells [63]. Hsp’s acting as virus recep-
tors on cell surfaces have been described in some viral
infections, e.g., rotaviruses [64], human T lymphotropic
virus Type 1 [65], coxsackievirus A9 [66] and DENV
[67]. The host protein plays a critical role in various
stages of the virus life cycle from entry, replication and
assembly to egress of the virus particles. Hsc70 has been
found to play a role in the life cycles of a variety of RNA
and DNA viruses [68]. Inhibitor for Hsc70 mRNA/pro-
tein expression could inhibit HBV/HCV replication
efficiently [69,70]. Medications that inhibit Hsc70 ex-
pression are effective in suppressing infection by wild-
type viral strains and effective against viral strains resist-
ant to lamivudine and suchlike medications, thus effect-
ively obviating HBV resistance to drugs. Unlike those
that target viral genes or enzymes, siRNA specific to
host Hsc70 genes would be effective against wild-type
and mutant drug-resistant HBV strains. By suppressingHsc70 mRNA expression in host cells, siHsc70 can
markedly suppress HBV replication [51,52]; drugs tar-
geted at Hsc70 are active against wild-type HBV while
simultaneously suppressing replication of viral strains re-
sistant to lamivudine, entecavir, telbivudine and kindred
drugs [69,70]. Because all HBV RNAs share common 3’
sequences, they may be targeted by a single siRNA. Rep-
lication of the virus is susceptible to RNAi-mediated in-
hibition and unlike HIV-1 or HCV, HBV genome is not
prone to mutation with escape from silencing by anti-
viral shRNAs. This is primarily because HBV has highly
compact genome with overlapping reading frames
(Additional file 1: Figure S1C). These factors might ex-
plain, at least in part, why these two HBV-specific
siRNAs have the highest efficacy. The two plasmids S1
and S2 we constructed were targeted at the conserved
region sequences in HBV genome subtype ayw, which
was identical with the virus we had previously reported
(GenBank accession number AY 517489 and AY
517619) [71]. The plasmids S1 and S2 are HBV-specific
Figure 4 (A, B, C, D) Effects of siRNAs on IFN-α, IFN-β, TNF-α in HEK293 and HepG2.2.15 cells. (A) HEK293 and HepG2.2.15 cells were
respectively transfected with pU6, S1, S2, S3, siHsc70, EGFP-siRNA and the positive-control poly (I:C). The concentrations of IFN-α, IFN-β and TNF-α
in cell culture supernatants from transfected cells were determined by ELISA assay. (B) The effects of siRNAs on the mRNA concentrations of IFN-
α, IFN-β, and TNF-α in HEK293 cells. HEK293 and HepG2.2.15 cells were respectively transfected with pU6, S1, S2, S3, siHsc70, EGFP-siRNA and the
positive-control poly (I:C). The mRNA concentrations of IFN-α, IFN-β and TNF-α were examined by RT-PCR amplification with the SYBR RT-PCR Kit.
Data represent means±SD from three independent experiments were performed in triplicate. (C) T98G cells were transfected with pU6, S1, S2, S3,
siHsc70, EGFP-siRNA and the positive-control poly (I:C). The concentrations of IFN-α, IFN-β and TNF-α in cell culture supernatants from transfected
cells were determined by ELISA assay. (D) The effects of siRNAs on the mRNA concentrations of IFN-α, IFN-β, and TNF-α in HEK293 cells. HEK293
cells were transfected with pU6, S1, S2, S3, siHsc70, EGFP-siRNA and the positive-control poly (I:C). The mRNA concentrations of IFN-α, IFN-β and
TNF-α were examined by RT-PCR amplification with the SYBR RT-PCR Kit. Data represent means±SD from three independent experiments were
performed in triplicate.
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HBVS; Hsc70 is a novel potential target for developing
drugs against HBV, and siHsc70 indirectly inhibits HBV
replication and expression by virtue of inhibiting host
proteins involved in HBV infection. Their target sites
and functioning mechanisms are different, but their
antiviral effects are the same and can work in synergy.
siRNAs directly targeting HBV genes are liable to for-
feit their inhibitory efficacy on account of HBV genes
mutating under selective pressure. The target site of
siHsc70 is on Hsc70, a host protein of remarkable sta-
bility, not subject to mutation under normal circum-
stances. In terms of inhibiting the expression of HBVSand e proteins, siHsc70 used in conjunction with S2 is
more potent than S2 or siHsc70 used in isolation by
6.3%, 6.9%, 18.8%, and 15.5% respectively. Most import-
antly, our results showed that combinational RNAi
markedly inhibited HBV protein, mRNA and HBV
DNA, resulting in up to a 3.36 log10 reduction in HBV
load in the HepG2.2.15 cell culture supernatants.
Hsc70 gene knockout generates no abnormality in
mice, proving its safety after inhibition of Hsc70 [45].
Therefore, The combined siRNAs exercising their effect
on Hsc70 can make up for flaws with S2 and thus can
not only inhibit wild-type HBV, but also can inhibit the
infectiousness of mutant strains as well. S3 did not
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siRNAs mediated significant reductions in a specific
target mRNA, and not a general down-regulation
resulting from activation of the dsRNA-activated pro-
tein kinase R (PKR), which could induce inhibition of
protein translation in a non-sequence specific manner.
As is well known, RNAi acts as a natural antiviral
defense mechanism in plants, especially against RNA
viruses. Mammalian cells were originally presumed to
be unlikely to inherently possess an active RNA-
silencing machinery, but primarily to induce a nonspe-
cific, interferon-mediated antiviral response mediated
by dsRNA, especially by viral long dsRNA. Some of the
siRNA sequences tested showed a vigorous IFN-a
response. Reportedly, in many cases transfection of
siRNAs (>35nt), even siRNAs (<23nt) results in IFN-
mediated activation of the Jak–Stat pathway and global
upregulation of IFN-stimulated genes (ISGs), which
was mediated by PKR and Toll-like receptors (TLRs).
Therefore, it may be that the innate immune system
can recognize immunostimulatory RNA motifs within
both single-stranded RNA (ssRNA) and double-
stranded RNA(dsRNA) via TLR7 or TLR8 [28–30].
Further work is required to define the core RNA motifs
underlying immune recognition of siRNA. TLR7 and
TLR8 have been shown to be restricted to cells of the
innate immune system. Previous studies [30,31]
reported the activation of the IFN pathway induction in
response to transcribed siRNAs in HEK293 and T98G
cells. The induction of the IFN and its effect on cellular
signalling pathways indicates that siRNAs have broad
effects beyond the selective silencing of homologous
target genes when introduced into cells.
The present study indicates that vector-based siRNA
without sequence of 5’ UGUGU 3’ and having lower
ratios of UG content minimize side effects on the innate
immune system [28]. Still, there have been studies
reporting different results, which indicates that the
mechanism in inducing innate IFN response is not redu-
cible to length and sequence dependence, and which
compels conjectures over the possible role that RNA
structures might play. As regards whether and how
siRNA can induce innate immune response in mamma-
lian cells, different studies have produced different
results. At present, there is no clear understanding of
the mechanisms that determine the gene-silencing effi-
ciency of a given siRNA. Viruses have evolved mechan-
isms to suppress or escape from RNAi. Strategies aimed
at providing rapid, efficient protection against HBV have
to surmount a major challenge—that is, acute infection
by the virus. Presumably siRNAs elicit an antiviral re-
sponse in cells within 24 h, promising development of
emergency RNAi vaccines to prevent virus disease, espe-
cially those capable of producing prompt prophylactic ortherapeutic effects against HBV. In addition to differ-
ences in the efficiency of gene silencing due to differ-
ences in the structures of siRNAs and of their targets, it
is suggested that other layers of complexity be
addressed, including the extent of conservation of the
RNAi machinery and its activity in many different mam-
malian cell types. There are still many hurdles to over-
come before RNAi is used to treat chronic HBV,
particularly relating to (i) appropriate delivery of RNAi
molecules and (ii) continual presence of cccDNA in the
hepatocyte nucleus which provides a constant source of
viral mRNAs and pregenome. However, our findings
suggest that combinational RNAi is worth pursuing in
developing new approaches to treat and cure the 400
million people worldwide living with chronic HBV infec-
tion. Further studies should be conducted with mam-
mals in order to obtain unanticipated results regarding
the aforementioned issues and therapeutic applications
of the combinational RNAi system.
In terms of viral clearance, our results highlight the
interest of a combined therapy. Such an approach is cap-
able of reducing the drug toxicity and preventing the
antiviral compound drug resistance, thus minimizing
chances of viral escape. The innovative combinational
RNAi approach to treating HBV is fundamentally dis-
tinct in that it inhibits viral expression as well as inhib-
ition of viral replication. Weakness in host immune
response associated with chronic HBV infection makes
it virtually impossible to achieve sustained, complete
viral clearance, even after long-term suppression of HBV
DNA replication with lamivudine or telbivudine, pre-
sumably because these therapies fail to reduce high viral
antigenemia believed to mitigate T cell response in
chronically infected patients and thereby help HBV avoid
immune clearance. In contrast, reducing viral antigen
levels attained after combinational RNAi-mediated deg-
radation of viral RNA transcripts (pregenomic RNA,
precore/ HBsAg mRNAs) may relieve the negative effect
of chronic antigen stimulation on T cell response and
facilitate recovery of that immune response. Since cer-
tain viral proteins, as the HBeAg, have been reported to
suppress innate immune responses that inhibit viral per-
sistence, reduction of viral protein synthesis could be an
additional benefit of RNAi -mediated therapy.
In little more than a decade, RNAi discovery has led
to understanding the molecular processes responsible
for small RNA biogenesis and function, as well as to
developing reagents that utilize the power of the RNAi
pathway. Notwithstanding the numerous hurdles for
translating these technologies into therapy, such as
important considerations for therapeutic RNAi that
gene silencing approaches rarely remove 100% of a
transcript, that off-target silencing can occur and that
each target organ, cell type and target transcript
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results warrant guarded optimism.
Conclusion
In summary, we have demonstrated for the first time
that combinational RNAi is specific and highly effect-
ive in suppressing ongoing viral gene expression and
replication in HepG2.2.15 cells while forestalling es-
cape by mutant HBV. The combined siRNAs were
more potent than HBV siRNA or siHsc70 used separ-
ately, without triggering interferon response or produ-
cing any side effects. This approach markedly
inhibited HBV protein, mRNA and HBV DNA, result-
ing in up to a 3.36 log10 reduction in HBV load in the
HepG2.2.15 cell culture supernatants. The antiviral
synergy of siHBV in combination with siHsc70 pro-
duced no cytotoxicity and induced no production
of IFN-α, IFN-β and TNF-α in transfected cells.
Although this approach should prove to be an effective
therapy against HBV, clinical application remains to be
further tested and examined. Nonetheless, the data
presented here justify continued explorations into this
innovative combinational RNAi approach to treating
HBV/HCV and HIV infection.
Materials and methods
Selection of target sequences
The reference sequences of the conserved regions
of HBV genome were obtained from the National
Center for Biotechnology Information (NCBI) website
(www.ncbi.nlm.nih.gov) and compared with those of
HBV by nucleotide (nt) BLAST. The genes and the
regions of interest were essential during the life cycle
of the virus and relatively conserved at the nucleo-
tide sequences, as diagrammed in Additional file 1:
Figure S1C.
HBV target sequences were chosen in regions overlap-
ping the viral 3.5-kb, 2.4-kb, and 2.1-kb RNAs, accord-
ing to the parameters indicated on the siRNA Target
Finder web site (www.ambion.com). The 21 nt target
sequences were selected as potential siRNA target sites
based on the S gene targeted at conserved regions in the
HBV genome originating from HepG2.2.15 cells (Stable
HBV DNA-producing cell lines, subtype ayw, GenBank
accession number U95551) [72]. Comparison of the
HBV genome sequences (subtype ayw, GenBank acces-
sion number U95551) with HBV subtype ayr (GenBank
accession number NC003977), adw(GenBank accession
number EF103278), and adr (GenBank accession number
AB299858) genome sequences by means of DNA STAR
software MegAlign showed that the two 21-nt siRNAs tar-
geting the HBVS gene were respectively homologous
with subtype ayw 357 nt—377nt and 421nt—441nt.
Through sequential analysis we found that the sequencehomologous with S1 exhibited two mutant points—359 nt
and 369 nt—in the four subtypes of HBV genome
sequences, and that the sequence homologous with S2 had
only one mutant point, 438nt (Additional file 3 Figure S3
and Additional file 4: Figure S4). In theory, siRNAs targeted
at fewer mutant points in the HBV genome would exercise
cross-inhibitory effects on various subtypes.Plasmid construction
We constructed two plasmids (S1 and S2) expressing
shRNAs targeting S sequences of HBV from GenBank
sequence data (accession number U95551) and one
Hsc70-specific siRNA-expressing plasmid (siHsc70), and
we used the control EGFP-specific siRNA plasmid
( siEGFP), as we had previously described methods
[33, 56]. The siHsc70 is identical in construction to two
shRNA-expressing plasmids. Briefly, the mouse U6 pro-
moter (pU6) was chemically synthesized from GenBank
sequence data (accession number X06980) and cloned
into the NdeI/EcoRI sites of pcDNA3.1B (−) vector
(Invitrogen), replacing the human cytomegalovirus pro-
moter (pCMV), to generate the parent vector pU6.
Then, inverted repeats targeting the genome of HBV
(Additional file 1: Figure S1C) were subcloned into pU6
at the EcoRI/HindIII sites, under the control of pU6 and
a termination signal of five thymidines (Ts) (Additional
file 1: Figure S1A). Plasmid S1 contains an inverted re-
peat corresponding to nt 201 to nt 221 of the DNA of
HBVS, while plasmid S2 contains an inverted repeat cor-
responding to nt 265 to nt 285 of the DNA of HBVS. As
a control for nonspecific effects, we used the shRNA-
expressing plasmid S3 containing an inverted repeat of
21nt heterologous to the HBV genome, as confirmed by
sequence analysis. To provide a reporting system for
evaluating the gene-silencing efficacy of siRNAs, the
DNA (681 nt) of HBVS was obtained by RT-PCR
with DNA extracted from HepG2.2.15 cells as
the template, using the primers 5’-CCGAAGCT
TATGGAGAACATCACATCAGGA-3’(sense) and 5’-CG
GCGAATTCAATGTATACCCAAAGACAAAAG-3’(anti-
sense). Primers for retrotranscription of EGFP mRNA were
5’- GCCACCATGGTGAGCAAG-3’(sense) and 5’-CC
CGCTTTACTTGTACAGC-3’ (antisense). RT-PCR pro-
ducts were further cloned into T-vector for sequencing [33,
50]. The pS-EGFP-N1 was generated by cloning the DNA
of HBV S into the EcoRI-BamHI sites of pEGFP-N1vector
(Clontech, Palo Alto, CA) to form fusion EGFP (Additional
file 1 Figure S1B) and reporter plasmids pS1-EGFP-N1,
pS2-EGFP-N1, pS3-EGFP-N1 and psiEGFP-N1 were con-
structed respectively using previously reported methods
[33,50,51,56]. The correct open reading frames con-
firmed by sequencing retained the fluorescent proper-
ties of the fusion protein.
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Three human cell lines, HepG2.2.15, HEK293, and
T98G, were obtained from the ATCC. All cells were cul-
tured in Dulbecco’s modified Eagle medium (DMEM,
Invitrogen, CA)) supplemented with 10% fetal calf serum
(Invitrogen), 100 units/ml penicillin/streptomycin, and
2% L-glutamine at 37°C with 5% CO2. HepG2.2.15 cells
were additionally maintained in medium containing
380 μg/ml G418. The day before transfection, cells were
seeded into 24-well plates (approximately 8 × 104 cells/
well) to achieve 60%-80% confluent cell monolayers.
HepG2.2.15 cells were transfected with 0.8 μg of
shRNA-expressing plasmids; HEK293 and T98G cells
were transfected with reporter/target plasmids (0.6 μg)
and either shRNA-expressing plasmids (0.3 μg) or pU6
(0.3 μg) or in combination, using Lipofectamine ™ 2000
(Invitrogen) according to the protocol provided by the
manufacturer. Transfection efficiency was calculated as
the ratio between the number of viable transfected cells
versus non-transfected cells. In our experiments, trans-
fection efficiency was routinely above 90%.
EGFP expression assay
To evaluate an effective inhibitory efficacy of siRNAs
on expression of EGFP, cotransfected cells were iden-
tified as EGFP positive cells by fluorescence micros-
copy and flow cytometry ((Becton Dickinson, San
Jose, CA). After an additional 24 h of incubation,
cells were observed for the expression of EGFP on an
Olympus BH-2 microscope and photographed using a
Nikon E950 video camera at a magnification of × 10
with an exposure time of 4 s. Cells were further sub-
jected to fluorescence-activated cell sorting, using pre-
viously described methods [33,50,51,56,59]. Silencing
efficiencies were quantified by flow cytometry. Spe-
cific silencing of target genes was confirmed by RT-
PCR and sequencing. Primers for retrotranscription of
EGFP mRNA were 5’- GCCACCATGGTGAGCA
AG-3’(sense) and 5’-CCCGCTTTACTTGTACAGC-3’
(antisense). RT-PCR products were cloned into T-
vector for sequencing [33,50–52].
Detection of Hsc70 protein by western blotting
Equal numbers of HepG2.2.15 cells transfected with
siHsc70 or pU6-siRNA-Ctrl (heterologous to Hsc70 se-
quence) after 72 h were lysed in SDS sample buffer. As
depicted in Figure 2A, cell lysates were separated by12%
SDS-PAGE and the proteins transferred onto a polyviny-
lidene fluoride (PVDF) membranes (Millipore) using a
Semi-Dry Electrophoretic Transfer System (Bio-Rad,
CA) , and then probed with monoclonal antibodies
specific for Hsc70 (clone 1B5; Stressgen) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
followed by incubation with horseradish peroxidase-labeled goat anti-mouse IgG as secondary antibody
(Santa Cruz Biotechnology). Bound antibodies were
detected by enhanced chemiluminescence (ECL) Plus
Western blotting detection reagents (PerkinElmer
Life Sciences). Hsc70 protein expression was also
examined by flow cytometry using previously described
methods [58,59].RNA preparation and RT-PCR
To detect HBV replication, total RNA was extracted from
HepG2.2.15 cell cultures by Qiagen Rneasy Mini Kit, and
subjected to quantitative real-time reverse transcription-
PCR (RT-PCR). In brief, RT-PCR was performed in 24-
well plates (Bio-Rad, Hercules, CA) in 20-μl reaction
volumes containing the components of a SYBR RT-PCR
Kit (Perfect Real Time; TaKaRa, Kyoto, Japan). The 20 μl
reaction mixture contained 10 μl of SYBR master mix
(2×), 0.4 μl of 0.2 μM forward primer and reverse primer
respectively, 2.0 μl of a 1 μg RNA sample, and 7.2 μl of
water. The cycle program consisted of 5°C for 30 min and
95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°
C for 20 s. Primers for retrotranscription of HBVS mRNA
were 5’-TCACAATACCGCAGAGTC-3’(sense), and 5’-
ACATCCAGCGATAACCAG-3’(antisense). To confirm
specific amplification, melting-curve analysis of the RT-
PCR products was performed according to the manufac-
turer’s protocol. Fluorescence was measured after
each cycle and displayed graphically with iCycler iQ Real-
Time PCR Detection System Software Version3.0A
(Bio-Rad, Hercules, CA). GAPDH was used as an internal
control, with 5’-CGGATTTGGTCGTATTGGG-3’(sense)
and 5’- TCTCGCTCCTGGAAGATGG-3’(antisense) as
primers. The cycle program employed was the same as
the cycling parameters for Q-RT-PCR described above.
Relative mRNA levels of HBVS were quantitated as the
ratio of the HBVS gene product quantity to 1 ng GAPDH.
RT-PCR products were cloned into T-vector for sequen-
cing. The amounts of Hepatitis B surface antigen (HBsAg)
and e antigen (HBeAg) in cell culture supernatants
were quantified using commercial ELISA kits (Abbott
Laboratories, North Chicago, IL). Assays were performed
in triplicate independent experiments.Quantitation of HBV progeny DNA in culture
supernatants
To measure the viral load, HBV DNA was extracted from
HepG2.2.15 cell culture supernatants using a QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany), and the HBV
DNA level was quantified using the Roche Diagnostics
Cobas Taqman 48 (Meylan, France), which has a detection
limit of 300 HBV DNA copies/ml. HBV genotypes were
identified using S gene fragment sequencing.
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The MTT cell viability assay has been described previ-
ously [45]. Briefly, HepG2.2.15 cells were plated in 24-
well plates at a density of 105 cells/well and transfected
with plasmids either individually or in combination or
with a nonspecific control siRNA. After being trans-
fected for 24 h or 48 h, cell proliferation (or cellular
toxicity) was analyzed by an MTT assay. For each MTT
assay, the medium in each well was replaced with 400 μl
of medium containing MTTat 0.5 μg/μl. After 4 h of incu-
bation, the MTT-containing medium was removed, 400 μl
of DMSO were added to each well, and the plate was agi-
tated for 10 min in the dark to dissolve the MTT-
formazan crystals. Sample absorbance was measured at
570 nm. The above experiments were performed in tripli-
cate and the results are presented as the mean±SD.Assay of HEK293, T98G cells and HepG2.2.15 cells for IFN-
α, IFN-β and TNF-α
To evaluate the potential effect of siRNAs on innate
IFN response in human cells, HEK293, T98G cells
and HepG2.2.15 cells were respectively transfected
with pU6, S1, S2, S3, siHsc70, siEGFP and the posi-
tive control 0.8 μg poly (I:C) (sigama, USA), and
then cell culture supernatants were harvested 48 h
post-transfection to detect cytokine. The concentra-
tions of IFN-α, IFN-β and TNF-α in cell culture
supernatants from transfected cells were determined
by ELISA. Meanwhile, the mRNA concentrations of
IFN-α, IFN-β and TNF-α were analyzed by RT-PCR
in every three cell lines. The cDNA was used as the
template for quantitative RT-PCR amplification with
the SYBR RT-PCR Kit. The method of extracting
RNA and the reverse transcription program was the same
as mentioned above. Three pairs of primers used respect-
ively for RT-PCR were: 5’-TTTGCTTTACTGGTGGCC-
3’(sense) 5’-GGGATGGTTTCAGCCTTT-3’(antisense)
for IFN-α; 5’-ACAGGTAGTAGGCGACAC-3’(sense) 5’-
GTTCTGGAGCATCTCATAG -3’(antisense) for IFN-β;
5’-AAGCAACAAGACCACCACTTCG-3’(sense) 5’- TCT
CCAGATTCCAGATGTCAGGG-3’(antisense) for TNF-
α. The thermocycling programs of quantitative RT-PCR
were the same except the annealing temperature with
62°C for IFN-α, 60°C for IFN-β, and 59°C for TNF-α.
GAPDH was used as an internal control, and the primers
employed were the same as the primers for RT-PCR
described above. Assays were performed in triplicate inde-
pendent experiments.
Statistical analysis
Statistical analysis was performed with Excel and with
SPSS software (version 11.0; Chicago, IL). All compara-
tive analyses were made using two-tailed hypothesis testsand Student’s t-test (P values of 0.05 or less were
regarded as significant difference).
Additional files
Additional file 1: Figure S1. Schematic diagrams of shRNA-expressing
cassette, EGFP reporter system, target constructs, and target viral mRNA.
(A) An inverted repeat corresponding to each of the target sequences in
the HBV genome was inserted under the control of pU6 and a
transcriptional termination signal of five Ts. As a result, transcription of
the shRNA-coding insert could be driven by pU6. The synthesized RNAs
should therefore fold back to form two types of shRNAs that are finally
processed into the putative siRNAs. (B) Diagram of the reporter system.
To provide a reporting system for evaluating the gene-silencing efficacy
of siRNAs, the DNA of HBVS was cloned into pEGFP-N1 and pcDNA3.1B
(⇀) vectors as described in Materials and Methods. (C) The HBV genome
contains four overlapping open reading frames. The arrows above show
the sites targeted by HBVS-specific shRNAs.
Additional file 2: Figure S2. Effect of siRNAs on the expression of HBV
surface open reading frame in HEK293 and T98G cells. (A) Fluorescence
micrographs of cells transfected with reporter plasmids and cotransfected
with either the corresponding or non-corresponding siRNA with
Lipofectamine TM 2000 (Invitrogen). At 24 hrs after transfection, the cells
were observed with an Olympus BH-2 microscope, and representative
bright-field images (left column) and relative fluorescent-field images
(right column) were recorded by fourfold amplification. (B) Flow
cytometry analysis of siRNA-mediated gene silencing of EGFP. EGFP
expression in cells cotransfected with (a) pEGFP-N1 vector; ( b) pEGFP-N1
and siEGFP; (c) pEGFP-N1 and pU6; (d) pEGFP-N1 and S3(heterologous
siRNAs) . The mean fluorescence intensity of control siRNA was taken as
100% and adopted as control. Data represent means±SD from three
independent experiments carried out in triplicate.
Additional file 3: Figure S3. (A) siRNA1 target sequences in various
subtype sequences of HBV genome selected for homologous sequential
analysis. (B) siRNA2 target sequences in various subtype sequences of
HBV genome selected for homologous sequential analysis.
Additional file 4: Figure S4. siRNA2 target sequences in various
subtype sequences of HBV genome selected for homologous
sequential analysis.
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